Apeiron Biologics
4 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19 (NCT05065645) | Apeiron Biologics | 2021-10-19 |
| Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 (NCT04335136) | Apeiron Biologics | 2020-04-30 |
Track Apeiron Biologics automatically
Every clearance here is in the API, with alerts when new ones post.